MX2022002415A - Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos. - Google Patents

Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos.

Info

Publication number
MX2022002415A
MX2022002415A MX2022002415A MX2022002415A MX2022002415A MX 2022002415 A MX2022002415 A MX 2022002415A MX 2022002415 A MX2022002415 A MX 2022002415A MX 2022002415 A MX2022002415 A MX 2022002415A MX 2022002415 A MX2022002415 A MX 2022002415A
Authority
MX
Mexico
Prior art keywords
breast cancer
methods
estrogen receptor
treating breast
tetrahydronaphthalene derivatives
Prior art date
Application number
MX2022002415A
Other languages
English (en)
Inventor
Yimin Qian
John Flanagan
Andrew P Crew
Jing Wang
Xin Chen
Sheryl Maxine Gough
Iii Royal J Haskell
Marcia Dougan Moore
Ian Charles Anthony Taylor
Original Assignee
Arvinas Operations Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arvinas Operations Inc filed Critical Arvinas Operations Inc
Publication of MX2022002415A publication Critical patent/MX2022002415A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente solicitud se refiere al tratamiento y/o la prevención del cáncer de mama, que incluye cáncer de mama ER+, HER2- localmente avanzado o metastásico, en un sujeto que necesita tratamiento, que comprende administrar un compuesto de la Fórmula (I), (ver Fórmula) (I), o una sal, enantiómero, estereoisómero, solvato, polimorfo, derivado isotópico o profármaco farmacéuticamente aceptable de este, en donde R1, R2, R3, R4, m y n se definen en la presente descripción.
MX2022002415A 2019-08-26 2020-08-24 Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos. MX2022002415A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962891648P 2019-08-26 2019-08-26
US201962924653P 2019-10-22 2019-10-22
US201962942663P 2019-12-02 2019-12-02
US202063023067P 2020-05-11 2020-05-11
PCT/US2020/047693 WO2021041348A1 (en) 2019-08-26 2020-08-24 Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders

Publications (1)

Publication Number Publication Date
MX2022002415A true MX2022002415A (es) 2022-03-22

Family

ID=72381146

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002415A MX2022002415A (es) 2019-08-26 2020-08-24 Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos.

Country Status (12)

Country Link
US (1) US20210060008A1 (es)
EP (1) EP4021450A1 (es)
JP (1) JP2022546471A (es)
KR (1) KR20220054347A (es)
CN (1) CN114667147A (es)
AU (1) AU2020336309A1 (es)
BR (1) BR112022003490A2 (es)
CA (1) CA3152401A1 (es)
CO (1) CO2022002729A2 (es)
IL (1) IL290789A (es)
MX (1) MX2022002415A (es)
WO (1) WO2021041348A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS64976B1 (sr) 2016-12-01 2024-01-31 Arvinas Operations Inc Derivati tetrahidronaftalena i tetrahidroizohinolina kao degradatori estrogenih receptora
TW202237117A (zh) * 2020-12-14 2022-10-01 美商亞文納營運公司 使用四氫萘衍生物作為雌激素受體降解劑治療乳癌之方法
MX2023011166A (es) * 2021-03-29 2023-09-29 Jiangsu Hengrui Pharmaceuticals Co Ltd Compuesto de tetrahidronaftaleno, metodo de preparacion y uso del mismo en medicina.
CN117229286A (zh) * 2022-06-14 2023-12-15 海创药业股份有限公司 一种芳香类化合物及其制备方法及在制备雌激素受体降解剂中的用途
WO2024015412A1 (en) * 2022-07-12 2024-01-18 Regents Of The University Of Michigan Tetrahydronaphthalene derivatives as estrogen receptor degraders
WO2024049922A1 (en) 2022-08-31 2024-03-07 Arvinas Operations, Inc. Vepdegestrant for use in treating cancer
WO2024049926A1 (en) 2022-08-31 2024-03-07 Arvinas Operations, Inc. Dosage regimens of estrogen receptor degraders
WO2024067781A1 (zh) * 2022-09-29 2024-04-04 江苏恒瑞医药股份有限公司 一种四氢萘类衍生物的可药用盐、晶型及制备方法
WO2024119081A1 (en) 2022-12-02 2024-06-06 Arvinas Operations, Inc. Method of treating breast cancer
CN116751186A (zh) * 2022-12-23 2023-09-15 南京知和医药科技有限公司 一种雌激素受体调节剂的制备及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
CA2645566A1 (en) * 2006-03-20 2007-09-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
US20180228907A1 (en) * 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
SG11201806251WA (en) * 2016-03-15 2018-08-30 Merrimack Pharmaceuticals Inc Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
RS64976B1 (sr) 2016-12-01 2024-01-31 Arvinas Operations Inc Derivati tetrahidronaftalena i tetrahidroizohinolina kao degradatori estrogenih receptora
JP2020506922A (ja) * 2017-01-31 2020-03-05 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． セレブロンリガンド、およびセレブロンリガンドを含有する二官能性化合物

Also Published As

Publication number Publication date
WO2021041348A1 (en) 2021-03-04
JP2022546471A (ja) 2022-11-04
CA3152401A1 (en) 2021-03-04
EP4021450A1 (en) 2022-07-06
CN114667147A (zh) 2022-06-24
AU2020336309A1 (en) 2022-03-17
BR112022003490A2 (pt) 2022-05-24
IL290789A (en) 2022-04-01
US20210060008A1 (en) 2021-03-04
CO2022002729A2 (es) 2022-04-08
KR20220054347A (ko) 2022-05-02

Similar Documents

Publication Publication Date Title
MX2022002415A (es) Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos.
MX2022008066A (es) Compuestos triciclicos sustituidos.
MX2022004808A (es) Métodos para tratar el cáncer de próstata.
MX2023001876A (es) Derivados de rapamicina.
MX2019011530A (es) Saxitoxinas 11,13-modificadas para el tratamiento del dolor.
MX2020001235A (es) Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona.
PH12016502354A1 (en) Pharmaceutical composition
MX2010001189A (es) Derivados de naftiridina como modulares del canal de potasio.
PH12019550111A1 (en) Pyran derivatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors
MX2023007058A (es) Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos.
MX2009009574A (es) Tratamiento de melanoma.
ZA202100485B (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
MX2013012588A (es) Inhibidores de cinasa.
MX2022014192A (es) Metodos para tratar el cancer de prostata.
MX336505B (es) Metodos y composiciones para reducir la grasa y los adipocitos del cuerpo.
SA520411635B1 (ar) A2a مشتق حلقي مدمج كمثبط مستقبل
MX2023006883A (es) Metodos para tratar el cancer de prostata.
MX2022009736A (es) Compuestos y metodos de p2x3 y/o p2x2/3.
MX2021003842A (es) Terapia combinada para el tratamiento del cancer.
MX2020010618A (es) Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a.
PH12019550154A1 (en) Azetidine derivative
TNSN07294A1 (en) Treatment of metastasized tumors
MX2022016554A (es) Métodos de tratamiento del cáncer mediante derivados heteroaril-bifenil-amida.
MX2023001671A (es) Procedimiento y compuesto para su uso en el tratamiento y/o prevención de la netosis.
MX2018008799A (es) Derivado de azaciclo amida, metodo de preparacion del mismo y aplicacion farmaceutica.